BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palmer EC, Binns LN, Carey H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Ann Pharmacother 2014;48:1030-9. [DOI: 10.1177/1060028014535074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Huang Q, Zhong X, Yun Y, Yu B, Huang Y. Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2016;12:2707-14. [PMID: 27822042 DOI: 10.2147/NDT.S114955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bruno A, Morabito P, Spina E, Muscatello MR. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Curr Neuropharmacol 2016;14:191-9. [PMID: 26572745 DOI: 10.2174/1570159x14666151117122458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
3 Li Y, Feng H, Gong W, Yu F, Xie X, He X, You-zhi Z, Mei X. Determination of Pharmacokinetics Differences of Ammuxetine Isomers in Rat Plasma Using On-Line Solid Phase Extraction Coupled with Liquid Chromatography-Tandem Mass Spectrometry. Chinese Journal of Analytical Chemistry 2014;42:1717-22. [DOI: 10.1016/s1872-2040(14)60787-8] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Paolucci S. Advances in antidepressants for treating post-stroke depression. Expert Opin Pharmacother 2017;18:1011-7. [PMID: 28535081 DOI: 10.1080/14656566.2017.1334765] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 9.8] [Reference Citation Analysis]